Skip to main content
Clinical Trials/NCT03864809
NCT03864809
Unknown
Not Applicable

• Sleep Disturbance Among Patients With Psoriasis and Atopy and Comparison Between Them

Assiut University0 sites150 target enrollmentJune 1, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Sleep Disturbance
Sponsor
Assiut University
Enrollment
150
Primary Endpoint
severity of the psooriasis (Psoriasis Area and Severity Index)
Last Updated
7 years ago

Overview

Brief Summary

Comparison between sleep disturbance in atopy and psoriasis and control

Detailed Description

Sleep is essential for daytime functioning and health and important for both psychological and physiological wellbeing . A growing body of research indicates that chronic sleep disturbance is associated with impaired quality of life (QoL) and a risk factor for poorer health, for example depression cardiovascular disease, hypertension 1 and diabetes. insomnia, the most common sleep disorder, is a clinical condition defined as difficulties falling asleep and/or maintaining sleep and/or poor sleep quality despite adequate opportunity for sleep resulting in significant daytime impairment. The development of insomnia in healthy populations has a bi-directional relationship with psychological factors such as anxiety, depressive symptoms and stress, and may in clinical populations also be associated with physical symptoms, such as pain. the physical symptoms in psoriasis, such as itch, one would expect a higher prevalence of sleep disturbance in this patient group. On the other hand Sleep disturbance is common also in patients with atopic dermatitis (AD). Patients with AD often have sleep disturbances due to pruritus.

Registry
clinicaltrials.gov
Start Date
June 1, 2019
End Date
August 2020
Last Updated
7 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Amani Mahmoud Abdelmohsen

Principal Investigator

Assiut University

Eligibility Criteria

Inclusion Criteria

  • patients with Psoriasis and Patients with A topic dermatitis

Exclusion Criteria

  • All patient have another dermatological disease

Outcomes

Primary Outcomes

severity of the psooriasis (Psoriasis Area and Severity Index)

Time Frame: 1 hour

calculation of the severity through questionaire , 0 = None 1. = Slight 2. = Moderate 3. = Severe 4. = Very severe

Secondary Outcomes

  • 2.HRQoL (Dermatology Life Quality Index);(1 hour)
  • .insomnia severity [Insomnia Severity Index (ISI)];(1 hour)
  • sleep quality [Pittsburgh Sleep Quality Index (PSQI)];(1 hour)
  • stress (Perceived Stress Scale);(1 hour)
  • itch (Itch Severity Scale);(1 hour)
  • and depressive symptoms (Beck Depression Inventory(1 hour)
  • severity of a topic dermatitis(1 hour)

Similar Trials